<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H937F7CF808B2407D85EF95BA53382433" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 9297 IH: Pre-Approval Information Exchange Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-11-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 9297</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20221115">November 15, 2022</action-date><action-desc><sponsor name-id="G000558">Mr. Guthrie</sponsor> (for himself, <cosponsor name-id="E000215">Ms. Eshoo</cosponsor>, <cosponsor name-id="G000568">Mr. Griffith</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="B001248">Mr. Burgess</cosponsor>, and <cosponsor name-id="M001163">Ms. Matsui</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to facilitate the exchange of certain product information, and for other purposes.</official-title></form><legis-body id="H58728244261D4B2E96E1FACB3C78C7A6" style="OLC"><section id="HC3B80D540320426CADC706B087432AEA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Pre-Approval Information Exchange Act of 2022</short-title></quote>. </text></section><section id="H71728B9BDB0A4FE39154EF025D943AE5"><enum>2.</enum><header>Facilitating exchange of product information prior to approval</header><subsection id="H597204EB22184A45A78F96906884993D"><enum>(a)</enum><header>In general</header><text>Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended—</text><paragraph id="HD9924ADBB03645558F39E2C29EBD50AA" commented="no"><enum>(1)</enum><text>in paragraph (a)—</text><subparagraph id="H7CF9FB1227CA490CBFFB5501B6B5E887"><enum>(A)</enum><text>by striking <quote>drugs for coverage</quote> and inserting <quote>drugs or devices for coverage</quote>; and</text></subparagraph><subparagraph id="H5A10F3FD573947FBB1AC4BB1A2F651EC"><enum>(B)</enum><text>by striking <quote>drug</quote> each place it appears and inserting <quote>drug or device</quote>, respectively;</text></subparagraph></paragraph><paragraph id="H7AB5F6F89641427780D5ECB67016C8FF" commented="no"><enum>(2)</enum><text>in paragraphs (a)(1) and (a)(2)(B), by striking <quote>under section 505 or under section 351 of the Public Health Service Act</quote> and inserting <quote>under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>;</text></paragraph><paragraph id="H1FEA2126A9624175A09B6E6122920EBD" commented="no"><enum>(3)</enum><text>in paragraph (a)(1)—</text><subparagraph id="H0E91851DFCE2442FB5F9B738F5ADE21E" commented="no"><enum>(A)</enum><text>by striking <quote>under section 505 or under section 351(a) of the Public Health Service Act</quote> and inserting <quote>under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>; and</text></subparagraph><subparagraph id="H7FC925550F424648B194407B04340179" commented="no"><enum>(B)</enum><text>by striking <quote>in section 505(a) or in subsections (a) and (k) of section 351 of the Public Health Service Act</quote> and inserting <quote>in section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>; and </text></subparagraph></paragraph><paragraph id="H31D07D054498445D8A922206AA2CAF09"><enum>(4)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="HAE811D4929DE44B9BB4F6F5D77742355" display-inline="no-display-inline"><subsection id="HB0CF627766E34C6AB3AF2E6C3195853D"><enum>(gg)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H7B8BC707F2E240698A58A2F35FC15763"><enum>(1)</enum><text>Unless its labeling bears adequate directions for use in accordance with paragraph (f), except that (in addition to drugs or devices that conform with exemptions pursuant to such paragraph) no drug or device shall be deemed to be misbranded under such paragraph through the provision of product information to a payor, formulary committee, or other similar entity with knowledge and expertise in the area of health care economic analysis carrying out its responsibilities for the selection of drugs or devices for coverage or reimbursement if the product information relates to an investigational drug or device or investigational use of a drug or device that is approved, cleared, granted marketing authorization, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable), provided—</text><subparagraph id="H22DBC70E226A4E47A08FDE7D34D0CB33" indent="up1"><enum>(A)</enum><text>the product information includes—</text><clause id="H88D2274FCF0345DFA305B276F11961FD"><enum>(i)</enum><text>a clear statement that the investigational drug or device or investigational use of a drug or device has not been approved, cleared, granted marketing authorization<italic></italic>, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable) and that the safety and effectiveness of the drug or device or use has not been established; </text></clause><clause id="HE2D8BCD25DF347E1A144FA00B17573A5"><enum>(ii)</enum><text>information related to the stage of development of the drug or device involved, such as—</text><subclause id="HE937C1B4894D4B0E9C6EA75C378D3390"><enum>(I)</enum><text>the status of any study or studies in which the investigational drug or device or investigational use is being investigated;</text></subclause><subclause id="HEEBA5D4DF87B4BABB5C80797D2F3EBB4"><enum>(II)</enum><text>how the study or studies relate to the overall plan for the development of the drug or device; and</text></subclause><subclause id="H2B4D554F7FD34E6288C6E0B9D4D2B5CF"><enum>(III)</enum><text display-inline="yes-display-inline">whether an application, premarket notification, or request for classification for the investigational drug or device or investigational use has been submitted to the Secretary and when such a submission is planned; </text></subclause></clause><clause id="H0E3B6BA27E884857BC02264962B6B682"><enum>(iii)</enum><text>in the case of information that includes factual presentations of results from studies, which shall not be selectively presented, a description of—</text><subclause id="HF2DCAD34179541D1B841EE6E7C83CB54"><enum>(I)</enum><text>all material aspects of study design, methodology, and results; and</text></subclause><subclause id="HBED3FF769ADD4E5586F00D9DBB98512D"><enum>(II)</enum><text>all material limitations related to the study design, methodology, and results;</text></subclause></clause><clause id="H33E22DD4E947467CB4801F36807D05E3"><enum>(iv)</enum><text>where applicable, a prominent statement disclosing the indication or indications for which the Secretary has approved, granted marketing authorization<italic></italic>, cleared, or licensed the product pursuant to section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act, and a copy of the most current required labeling; and</text></clause><clause id="H3923104C425C49B5A43B915BA27B4D23"><enum>(v)</enum><text>updated information, if previously communicated information becomes materially outdated as a result of significant changes or as a result of new information regarding the product or its review status; and</text></clause></subparagraph><subparagraph id="HA2F58C6D77F94DC99AC5B96266E94195" indent="up1"><enum>(B)</enum><text>the product information does not include—</text><clause id="H984C1839ADC241EBA7A9FC69F6F5A17E"><enum>(i)</enum><text display-inline="yes-display-inline">information that represents that an unapproved product—</text><subclause id="HE0A0D1B835CE48249D66893286FA132F"><enum>(I)</enum><text>has been approved, cleared, granted marketing authorization, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable); or</text></subclause><subclause id="HEE0FA45A8DF6477BB153D3EDE8DB27E0"><enum>(II)</enum><text>has otherwise been determined to be safe or effective for the purpose or purposes for which the drug or device is being studied; or</text></subclause></clause><clause id="HEDF87C40559148848A131F55BB68559F"><enum>(ii)</enum><text>information that represents that an unapproved use of a drug or device that has been so approved, granted marketing authorization, cleared, or licensed—</text><subclause id="H73F535695CCB4F739C09895144DE02DD"><enum>(I)</enum><text>is so approved, granted marketing authorization, cleared, or licensed; or</text></subclause><subclause id="HC98DBCACFB574FF3BC29EA0610E00273"><enum>(II)</enum><text>that the product is safe or effective for the use or uses for which the drug or device is being studied.</text></subclause></clause></subparagraph></paragraph><paragraph id="HE342850F143842EE8EACE9743410E942" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">For purposes of this paragraph, the term <term>product information</term> includes—</text><subparagraph id="H7B3134DB7B7341519426CE86F3E8A1B1"><enum>(A)</enum><text>information describing the drug or device (such as drug class, device description, and features);</text></subparagraph><subparagraph id="H54509D52B6DB4BE6B85A9A6195517948"><enum>(B)</enum><text>information about the indication or indications being investigated;</text></subparagraph><subparagraph id="H2BEADE231F874500BAD986F95FE6A998"><enum>(C)</enum><text>the anticipated timeline for a possible approval, clearance, marketing authorization, or licensure pursuant to section 505, 510(k), 513, or 515 of this Act or section 351 of the Public Health Service Act;</text></subparagraph><subparagraph id="H03D136493B204A2C989639808F13B9AC"><enum>(D)</enum><text>drug or device pricing information;</text></subparagraph><subparagraph id="H7A95AA3D0F8245749C4EA00E2CF48EF6"><enum>(E)</enum><text>patient utilization projections;</text></subparagraph><subparagraph id="H14054B046AB043DE81B039E48D561B13"><enum>(F)</enum><text>product-related programs or services; and</text></subparagraph><subparagraph id="H06027B72C2594F39BF93540497087140"><enum>(G)</enum><text>factual presentations of results from studies that do not characterize or make conclusions regarding safety or efficacy.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HEC6E6486095E420384EDA1ECA8F9A487"><enum>(b)</enum><header>GAO study and report</header><text>Beginning on the date that is 5 years and 6 months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study on the provision and use of information pursuant to section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by this subsection (a), between manufacturers of drugs and devices (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>)) and entities described in such section 502(gg). Such study shall include an analysis of the following:</text><paragraph id="H0067F6E85FEB458180F715954BA6990A"><enum>(1)</enum><text>The types of information communicated between such manufacturers and payors.</text></paragraph><paragraph id="H89CD9B716C324B53A037C27520FA6C06"><enum>(2)</enum><text>The manner of communication between such manufacturers and payors.</text></paragraph><paragraph id="HB6F1B444A2B9467D90A0CD39C7CDAB8E"><enum>(3)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H91A7FE5300A3481691C769CC96AD30EB"><enum>(A)</enum><text>Whether such manufacturers file an application for approval, marketing authorization, clearance, or licensing of a new drug or device or the new use of a drug or device that is the subject of communication between such manufacturers and payors under section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a).</text></subparagraph><subparagraph id="H2FFEEAB7FB7E476CB0BE51CA225A56EE" indent="up1"><enum>(B)</enum><text>How frequently the Food and Drug Administration approves, grants marketing authorization, clears, or licenses the new drug or device or new use.</text></subparagraph><subparagraph id="HF2AC3F2BE71D4B308AEE6EAE33A40D0A" indent="up1"><enum>(C)</enum><text>The timeframe between the initial communications permitted under section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), regarding an investigational drug or device or investigational use, and the initial marketing of such drug or device.</text></subparagraph></paragraph></subsection></section></legis-body></bill> 

